Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Clinical and Radiographic Evaluation of E-IodoCal in Primary Molar Pulpectomy

NCT07883200 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-11-25
Last updated
2026-10-20

Condition(s) studied

PulpectomyPulpitis - IrreversibleZinc OxideRoot Canal Obturation

Investigational drug(s) / intervention(s)

E-IodoCal Root Canal Obturation (Group I)Zinc Oxide-Eugenol Root Canal Obturation (Group II)

E-IodoCal Root Canal Obturation (Group I): Chemo-mechanical preparation: Rubber dam isolation, access opening, pulp tissue removal, working length determination, manual instrumentation up to #30-#35 using 17% EDTA gel lubricant, and standard irrigation with 2.5% sodium hypochlorite and normal saline. Canals are dried with sterile paper points. Obturation: E-IodoCal paste delivered using its pre-packed polypropylene syringe inserted 1 mm short of the apex, withdrawing slowly as canals fill. Restoration: Intermediate glass ionomer base (Medifil) followed by a final stainless steel crown.

Zinc Oxide-Eugenol Root Canal Obturation (Group II): Preparation: Identical isolation, access, cleaning, shaping, and drying protocol as Group I. Obturation: ZOE paste carried into canals in small increments using a hand plugger rotated counterclockwise until complete obturation is achieved. Restoration: Identical glass ionomer base and final stainless steel crown placement.

Study summary

This randomized controlled split-mouth clinical trial evaluates the clinical and radiographic performance of E-IodoCal paste compared to zinc oxide-eugenol (ZOE) as root canal filling materials in primary molar pulpectomies.

Eligibility

Sex
ALL
Min age
4 Years
Max age
8 Years
Healthy volunteers
No
Inclusion Criteria: Clinical: - * Healthy cooperative children with an age range of 4 - 8 years. * Nonvital deep carious mandibular primary second molars with sufficient coronal structure and at least 2/3rd root structure intact. * Pulp exposure where bleeding couldn't be stopped following removal of the coronal pulp tissue * Previous history of irreversible pulpitis signs and symptoms as spontaneous pain, percussion sensitivity, fistulous tract related to the involved tooth, and pathologic tooth mobility (grade-I mobility) Radiographic: * Adequate alveolar bone support (coverage by the bone of minimum two- thirds of at least one root). * Presence of interradicular radiolucency (discontinuity of lamina dura and/or furcation involvement less than or equal to half of the shortest root). Exclusion Criteria: Clinical: * Non-restorable primary molars with severe mobility (greater than grade-I mobility). * Children with systemic illness (any medically compromising condition). * Primary molars beyond possible repair. Radiographic: * Extensive internal resorption. * Extensive external pathological root resorption. * Obliteration of the root canal. * Physiological root resorption of more than a third of its length.

Primary outcome measure(s)

  • Clinical Success Rate — Evaluated at 3, 6, and 9 months post-operative.
    Measure: Binary evaluation (Success/Failure) based on the complete absence of: Spontaneous or stimulated pain. Soft tissue swelling or draining sinus tract. Pathological tooth mobility. Tenderness to percussion / normal function on biting.
  • Radiographic Success Rate — Evaluated at 3, 6, and 9 months post-operative.
    Measure: Binary evaluation (Success/Failure) assessed via standardized digital periapical radiographs based on: Complete absence or reduction in size of periapical/interradicular radiolucency. Absence of pathological root resorption (internal or external). Normal, uniform, and unwidened periodontal ligament space with an intact, unbroken lamina dura.

Trial sites (1)

FacilityCityRegionStatus
faculty of dentistry, Tanta university Tanta Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07883200 on ClinicalTrials.gov ↗ ← All trials in Egypt